

## **CURRICULUM VITAE**

**Nathan B. Fountain, M.D.**

### **Personal Data:**

Work Address: University of Virginia School of Medicine  
Department of Neurology, Box 800394  
Charlottesville, VA 22908  
Phone: 434-243-6281, Fax: 434-982-1726  
E-mail: nbf2p@virginia.edu

### **Education:**

1981-1985 Bachelor of Science in Zoology with Highest Distinction, May, 1985  
University of Iowa, Iowa City, Iowa

1985-1989 Doctor of Medicine, May, 1989  
University of Iowa College of Medicine, Iowa City, Iowa

### **Post-graduate Training and Fellowships:**

1989-1990 Intern, Department of Internal Medicine  
University of Virginia, Charlottesville, Virginia

1990-1993 Resident, Department of Neurology  
University of Virginia, Charlottesville, Virginia

1992-1993 Chief Resident, Department of Neurology  
University of Virginia, Charlottesville, Virginia

1993-1994 Clinical Neurophysiology/EEG and Epilepsy Fellowship  
University of Virginia, Charlottesville, Virginia

1994-1996 Experimental/Clinical Epilepsy Fellowship  
University of Virginia, Charlottesville, Virginia

### **Academic Appointments:**

7/96-7/01	Assistant Professor, Department of Neurology University of Virginia School of Medicine, Charlottesville, Virginia
10/97-present	Director, F.E. Dreifuss Comprehensive Epilepsy Program University of Virginia School of Medicine, Charlottesville, Virginia
10/97- present	Director, EEG and Epilepsy Fellowships University of Virginia School of Medicine, Charlottesville, Virginia
2/98- present	Director, Rural Outreach Neurology Clinics University of Virginia Health Sciences Center, Charlottesville, Virginia
7/01-7/05	Associate Professor, Department of Neurology University of Virginia School of Medicine, Charlottesville, Virginia
7/05- 6/09	Associate Professor Without Term (tenure), Department of Neurology University of Virginia School of Medicine, Charlottesville, Virginia
7/09-present	Professor, Department of Neurology University of Virginia School of Medicine, Charlottesville, Virginia
8/18-present	The Thomas E. Worrell, Jr. Professor of Epileptology and Neurology University of Virginia School of Medicine, Charlottesville, Virginia

### **Certification:**

Federal Licensure Examination, 1989  
American Board of Psychiatry and Neurology - *Neurology* (#41246) 1995-2005, 2005-2015,  
2017-2027  
American Board of Psychiatry and Neurology - *Clinical Neurophysiology* (#1035), 1999-2009,  
2010-2020  
American Board of Psychiatry and Neurology - *Epilepsy* (#148), 2013-2023  
American Board of Clinical Neurophysiology, 1997 (permanent)

### **Licensure:**

Medical License for the Commonwealth of Virginia, 1992, exp 2/28/20 (#0101048670)  
Medical License for the State of Tennessee, 1997, inactive (#29963)

### **Honors and Awards:**

1985	Bachelor of Science with Special Honors
1982-1985	University of Iowa Honors Society Member
1982-1985	Iowa Foundation Scholarships

1984	Iowa Undergraduate Scholar
1985	University of Iowa Certificate of Achievement/Collegiate Scholar
1985	Medical Student Research Fellowship
1988	University of Iowa Class of 1934 Academic Scholarship
1989	Barry Freeman Fellowship for study in Papua New Guinea
1994	Epilepsy Foundation of America Clinical Research Grant
1995	Epilepsy Foundation of America Clinical Research Grant
1996	Alpha Omega Alpha Medical Honor Society
2007-present	Best Doctors in America
2007	Visiting Professorship, Ain Shams University, Cairo, Egypt
2010	Visiting Professorship, Anshan Changda Hospital, Anshan, China
2012	Keynote Speaker, Egyptian Society of Neurology Conference, Cairo
2016	Fellow, American Epilepsy Society
2018	Fellow, American Academy of Neurology

### **Professional Activities:**

#### **Editorial Boards**

2000-2005	<i>Micromedex Diseasedex</i>
2002-2007	<i>American College of Physicians - Physicians Information and Education Resource (PIER)</i>
2005-2014	<i>Epilepsy Currents</i>
2014-2016	Epilepsy.com, <i>Epilepsy &amp; Behavior</i> abstract and PAB section editor

#### **Journal Referee**

1995-present	<i>Neurology</i>
1997-2000	<i>CNS Drugs</i>
1998-1999	<i>Drug Safety</i>
1999-2000	<i>Sleep Research Online</i>
2000-present	<i>Epilepsia</i>
2003-2004	<i>Clinical Neuropharmacology</i>
2003-present	<i>Epilepsy and Behavior</i>
2003-2004	<i>JAMA, Journal of the American Medical Association</i>
2007	<i>Neuropsychiatric Disease and Treatment</i>
2007	<i>Clinical Pharmacokinetics</i>
2007	<i>Drug Design, Development and Therapy</i>
2008	<i>Acta Neurologica Scandinavica</i>
2008-present	<i>Epilepsy Research</i>
2008-present	<i>Journal of Pediatric Neurology</i>
2008-2010	<i>Mayo Clinic Proceedings</i>
2009	<i>European Journal of Neurology</i>
2009-present	<i>Clinical Neurophysiology</i>
2010-present	<i>Neurosurgery</i>
2011-present	<i>Annals of Neurology</i>
2012-present	<i>Seizure</i>
2013-present	<i>North African and Middle Eastern Epilepsy Journal</i>

**Grant and Federal Review Committees**

1998-1999	Scientific Review Committee, Comitato Telethon Grants, Rome, Italy
2000	Israel Science Foundation
2002	Georgian -U.S. Civilian Research and Development Foundation
2004	CDC Quality of Epilepsy Care Grant Review Panel, 2004-R19
2006	Epilepsy Quality of Care Measures, Expert Review Panel, Boston University
2007	CDC Epidemiology of Epilepsy Grant Review Panel, 2007-R05
2009	CDC Epilepsy Special Emphasis Panel 2009
2009-2010	FDA Peripheral and CNS Drugs Advisory Committee, consultant
2010-2014	FDA Peripheral and CNS Drugs Advisory Committee, member, chair (11-14)
2014-2017	FDA Peripheral and CNS Drugs Advisory Committee, consultant
2018-2022	FDA Peripheral and CNS Drugs Advisory Committee, chair 2/1/18-1/31/22
2010	EF Grant Review Panel, Targeted Initiative for Seniors
2010-2016	EF Grant Reviews (Morbidity and Mortality in Epilepsy, Section Head)
2017	FBI Critical Incident Response Group, consultant

**Professional Societies: National Offices and Committees**

American Academy of Neurology (AAN)

1999-2004	Epilepsy Education Committee
2001-2002	Practice Parameter Reviewer Network
2008-2015	Epilepsy Quality Performance Measures Work Group, Co-Chair
2009	Scientific Abstract Review Committee
2011	Neuropsychometric and Seizure Devices FDA Workshop Committee
2011	Epilepsy Quality Metrics Analysis Group
2014	Epilepsy Quality Measures Revision Work Group, Co-Chair
2014	Scientific Abstract Review Committee
2018	Fellow

American Epilepsy Society (AES)

2001-2004	Annual Course Committee
2002-2004	Scientific Program Committee
2007-2010	Annual Course Committee
2009-2016	Nonepileptic Seizures Task Force
2010-2014	EMU Safety Committee
2011-2013	Practice Management Committee, Quality Subcommittee chair
2016	Fellow

National Association of Epilepsy Centers (NAEC)

2005-present	Board of Directors
2010-2011	Treasurer
2011-2015	Vice President
2015-2019	President
2006	Epilepsy Quality Care Indicators Committee
2017-2019	AMA CPT Panel 95951 Applicant Group

American Clinical Neurophysiology Society (ACNS)  
 2005-2016 Critical Care Monitoring Committee  
 2008 Oral Board Examiner

Epilepsy Foundation (EF)  
 2007-2016 Professional Advisory Board (PAB)  
 Chair (2014-2016), Chair-elect (2011-2013),  
 2008-2013 PAB Quality of Life Committee, chair (2011-2013)  
 2010 PAB Epilepsy Referral Guidelines/Standards of Care Workgroup  
 2010 EF/NICHQ Educational Stakeholder Conference, member  
 2010-present Research Council  
 2015-present Research Roundtable, Founding Co-chair

Epilepsy Research Foundation (ERF), Epilepsy Therapy Project (ETP)  
 2011-present Board of Directors

American Board of Psychiatry and Neurology (ABPN)  
 2009-2013 Clinical Neurophysiology Maintenance of Certification Committee

American College of Emergency Physicians  
 2003 Policy Reviewer, Clinical Policies Committee

Vision 20/20  
 2010-2014 NAEC Representative  
 2011-2012 Institute of Medicine (IOM) “Epilepsy Across the Spectrum” report  
 2013 Intractable Epilepsy Awareness Web-based IOM Tool Development

**Professional Societies: Regional Offices and Committees**

Epilepsy Foundation of Virginia  
 1999-2002 Professional Advisory Board Member  
 2002-2009 President  
 2009-present Professional Advisory Board Chair

Virginia Neurological Society  
 2003-2005 Councilor  
 2005-2007 Treasurer  
 2007-2009 Vice-President  
 2009-2011 President Elect  
 2011-2013 President

**Professional Societies: Memberships**

1992-present American Academy of Neurology (AAN)  
 1996-present American Epilepsy Society (AES)  
 1998-present American Clinical Neurophysiology Society (ACNS)  
 1998-present National Association of Epilepsy Centers (NAEC)

**Grant Development Committees, Advisory Boards**

2003-2006 Epilepsy Development Advisory Board, Med Pointe Pharmaceuticals  
 2004-2008 Epilepsy Drug Development Advisory Board, UCB Pharma  
 2004-2008 Epilepsy Drug Development Advisory Board, Schwarz Biosciences  
 2006-2008 Monotherapy RCT Grant Development Committee (M. Privitera, PI)  
 2007 Schwarz SP902 Monotherapy Steering Committee

- 2008-2009 Prospective trial of levetiracetam for antiepileptogenesis after traumatic brain injury, Grant Development Committee (P. Klein, multicenter PI)
- 2010-2019 Established Status Epilepticus Treatment Trial (ESETT) Grant Development Committee and Clinical Adjudication Committee (J. Kapur, PI)
- 2015-2019 Adjudication Committee, Medtronic Registry for Epilepsy in Europe (MORE), Medtronic
- 2016-present Medical Monitor, Dose Ranging Study to Assess Intracerebroventricular (ICV) Valproate in Temporal Lobe Seizures, Cerebral Therapeutics
- 2019-2021 Genetic and protein biomarkers of post-traumatic epilepsy to improve prediction of PTE (PI: Klein) grant development committee, (P. Klein, PI)

**Institutional and Neurology Department Committees**

- 2002-2003 Multiple Sclerosis Faculty Search Committee
- 2002-2003 Pediatric Epilepsy Faculty Search Committee
- 2003-2007 Health Services Foundation, Physician Advisory Council
- 2004-2007 Epilepsy Faculty Search Committee
- 2005-2007 Research Administration and Compliance Computing Initiative
- 2008-2011 Dean’s Research Advisory Committee, Chair 2010
- 2008 Investigator Advisory Committee of Institutional Review Board
- 2010 Epic EMR Research Committee
- 2010 Epilepsy Neurology Faculty Search Committee
- 2010 Pediatric Neurology Faculty Search Committee
- 2010 Clinical Research Advisory Committee
- 2013-20188 Epic Research Advisory Committee

**School of Medicine Standing Teaching Assignments**

- 1994- 2017 Neurology Physical Diagnosis Section (POM), Founding Course Director
- 1996-2001 Clinical Neurophysiology Resident Lecture Series, Lecturer
- 1996-present Neurology Clerkship; Problem Set Discussion Preceptor, Lecturer
- 1997-present Epilepsy Fellows Weekly Reading Conference; Preceptor, Lecturer
- 1997-1998 Medical Neuroscience Course; Lecturer, Anatomy Lab Instructor, Case Discussion Preceptor
- 1998-1999 Graduate Dissertation Committee, Greg Harrington, Physics and Engineering Departments, “Fourier generated empirical functional MRI models”
- 1999-2016 Medical Scientist Training Program Practice of Medicine, Course Preceptor
- 1999-present Epilepsy Nurse Conference
- 2002-2003 Graduate Dissertation Committee, Teiko Miyashita, Department of Psychology, “Modulation of hippocampal noradrenergic systems as a neural substrate for memory enhancement initiated by peripheral arousal”

## **Grants and Contracts (last 5 years):**

### **Investigator Initiated Research Grants:**

- 2009-2014      Radiosurgery versus open surgery epilepsy trial (ROSE), R01 NS 058634-01A2, site PI (N. Barbaro, M. Quigg multicenter co-PIs)
- 2010-2014      Epilepsy Phenome/Genome Project (EPGP), NINDS U01 NS 053998, site PI (D. Lowenstein, multicenter PI)
- 2011-present    2-Deoxyglucose: Proof of Principal Clinical Trial, Epilepsy Research Foundation, PI (on hold)
- 2015-present    Focused Ultrasound for Subcortical Epilepsy (FUSE) study, PI, Epilepsy Foundation and InSightec
- 2015-2020      Established Status Epilepticus Treatment Trial (ESETT), 1U01NS088034-01, Adjudication Core (J. Kapur, multicenter PI)
- 2019-2021      Genetic and protein biomarkers of post-traumatic epilepsy to improve prediction of PTE: prospective study in enriched population (P. Klein, multicenter PI)

### **Clinical Drug and Device Epilepsy Trials, UVA Principal Investigator:**

- 2011-2014      Phase 3 RCT brivaracetam for partial seizures (N01358). UCB
- 2011-2017      Open-label long term study of brivaracetam (N01379). UCB
- 2013-2018      Dose ranging RCT of YKP3089 for partial seizures (C017). SK Life Sciences
- 2016-2018      PK Study of NRL-1: seizure and normal conditions (DIAZ.001.04). Neurelis
- 2016-2018      Repeat-Dose Safety Study of NRL-1 in Epilepsy (DIAZ.001.05). Neurelis
- 2016-present    YKP3089 PK/exposure study in partial onset seizures (C021). SK Life Sciences
- 2017-2018      Dose-escalation RCT of TAK-935 for epileptic encephalopathies (2001). Takeda
- 2017-2019      CBD for LGS open label extension (1415). GW Pharma
- 2018-present    CBD for TS and open label extension (1521). GW Pharma
- 2019-present    RCT efficacy study of Padsevoniil for focal seizures (EP0092), UCB
- 2019-present    RCT efficacy study of XEN1101 for focal seizures (XPF-008-201), Xenon

### **Public Health Care Grants:**

- 2003-present    Virginia Department of Health - Care Connection for Children. Administration of Neurology Southwest Virginia rural field clinics (\$68,000/year)

### **Peer Reviewed Publications:**

1.      **Fountain, N.B.**, Lothman, E.W. Pathophysiology of status epilepticus. Journal of Clinical Neurophysiology 1995;12(4):326-342.

2. **Fountain, N.B.**, Eberhard, D.A. Primary angiitis of the CNS associated with cerebral amyloid angiopathy: report of two cases and review of the literature. *Neurology* 1996;46:190-197.
3. Bear, J., **Fountain, N.B.**, Lothman, E.W. Responses of the superficial entorhinal cortex *in vitro* in slices from naive and chronically epileptic rats. *Journal of Neurophysiology* 1996;76(5):2928-2940.
4. **Fountain, N.B.**, Kim, J.S., Lee, S.I. Sleep deprivation activates epileptiform discharges independent of the activating effects of sleep. *Journal of Clinical Neurophysiology* 1998;15:69-75.
5. Fountain, N.B., Bear, J., Bertram, E.H., Lothman, E.W. Responses of deep entorhinal cortex are epileptiform in an electrogenic rat model of chronic temporal lobe epilepsy. *Journal of Neurophysiology* 1998;80:230-240.
6. Bertram, E.H., Zhang D.X., Mangan P., **Fountain, N.**, Rempe D. Functional anatomy of limbic epilepsy - a proposal for central synchronization of a diffusely hyperexcitable network. *Epilepsy Research* 1998;32:194-205.
7. **Fountain, N.B.**, Lopes, M.B.S. Control of primary angiitis of the CNS associated with cerebral amyloid angiopathy by cyclophosphamide alone. *Neurology* 1999;52(3):660-662.
8. Quigg, M., **Fountain, N.B.** Conduction aphasia elicited by stimulation of the left posterior superior temporal gyrus. *Journal of Neurosurgery, Neurology & Psychiatry* 1999;66:393-396.
9. **Fountain, N.B.**, Adams, R. E. Midazolam treatment of acute and refractory status epilepticus. *Clinical Neuropharmacology* 1999;22(5):261-267.
10. **Fountain, N.B.** Status epilepticus: risk factors and complications. *Epilepsia* 2000;41(Suppl 2):S23-S30.
11. Laxer K, and Ganaxolone Presurgical Study Group. Assessment of ganaxolone anticonvulsant activity using a randomized double-blind, presurgical trial design. *Epilepsia* 2000;41(9):1187-1194.
12. Frucht M.M., Quigg, M., Schwaner, C., **Fountain, N.B.** Distribution of seizure precipitants among epilepsy syndromes. *Epilepsia* 2000;41:1534-1539.
13. **Fountain, N.B.**, Waldman, W.A. Effects of benzodiazepines on triphasic waves: Implications for nonconvulsive status epilepticus. *Journal of Clinical Neurophysiology*, 2001;18(4):345-352.
14. Pellock JM, Glauser TA, Bebin EM, **Fountain NB**, Ritter FJ, Coupez RM, Shields WD. Pharmacokinetic Study of Levetiracetam in Children. *Epilepsia* 2001;42(12):1574-1579.
15. Glauser TA, Pellock JM, Bebin EM, **Fountain NB**, Ritter FJ, Jensen CM, Shields WD. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. *Epilepsia* 2002;43:518-524.

16. Quigg MS, Armstrong RF, Farace E, **Fountain NB**. Quality of life outcome is associated with cessation rather than reduction of psychogenic nonepileptic seizures. *Epilepsy and Behavior* 2002;3:455-459.
17. Gullapalli D, **Fountain NB**. Clinical correlation of occipital intermittent rhythmic delta activity (OIRDA). *Journal of Clinical Neurophysiology*, 2003;20(1):35-41.
18. Shneker BF, **Fountain NB**. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. *Neurology* 2003;61:1066-1073.
19. **Fountain, N.B.**, May A.C. Epilepsy and Athletics. *Clinics in Sports Medicine* 2003;33(3):605-616.
20. Kirby D, **Fountain NB**, Quigg MS. Standardized mental status testing for nonconvulsive status epilepticus. *American Journal of Electroneurodiagnostic Technology* 2004;44(3):199-201.
21. Sahoo SK, **Fountain NB**. Epilepsy in football players and other land-based contact/collision sport athletes: when can they participate and is there an increased risk? *Current Sports Medicine Reports*, 2004;3(5):284-5.
22. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, Lu Z for the N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. *Neurology*. 2006;66(11):1654-60.
23. **Fountain NB**, Conry JA, Rodríguez-Leyva I, Gutierrez-Moctezuma J, Salas E, Coupez R, Stockis A, Lu Z. Prospective Assessment of Levetiracetam Pharmacokinetics During Dose Escalation in 4- to 12-Year-Old Children With Partial-Onset Seizures on Concomitant Carbamazepine or Valproate. *Epilepsy Research* 2007;74:60-69.
24. Pugh MJ, Berlowitz DR, Montouris G, Bokhour B, Cramer JA, Bohm V, Bollinger M, Helmers S, Ettinger A, Meador KJ, **Fountain N**, Boggs J, Tatum WO 4th, Knoefel J, Harden C, Mattson RH, Kazis L. What constitutes high quality of care for adults with epilepsy? *Neurology* 2007;69:2020-2027.
25. Biton V, Rosenfeld WE, Whitesides J, **Fountain NB**, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures (SP616). *Epilepsia* 2008;49(3):418-424.
26. Fisher R for the SANTE Study Group. Electrical Stimulation of the Anterior Nucleus of Thalamus for Treatment of Refractory Epilepsy. *Epilepsia* 2010;51(5):899-908.
27. Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, Doty P; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. *Epilepsia* 2010;51(6):958-67.

28. Labiner DM, Bagic AI, Herman ST, **Fountain NB**, Walczak TS, Gumnit RJ; for the National Association of Epilepsy Centers. Essential services, personnel, and facilities in specialized epilepsy centers-Revised 2010 guidelines. *Epilepsia* 2010;51:2322-2333.
29. Chung S, Ben-Menachem E, Sperling M, Rosenfeld W, **Fountain NB**, Benbadis S, Hebert D, Isojarvi J, Doty P. Examining the Clinical Utility of Lacosamide: Pooled Analyses of Three Phase II/III Clinical Trials. *CNS Drugs* 2010;24(12):1041-1054.
30. **Fountain NB**, Van Ness PC, Swain-Eng R, Tonn S, Bever CT Jr; For the American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association–Convended Physician Consortium for Performance Improvement Independent Measure Development Process. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. *Neurology* 2011;76(1):94-99.
31. Morrell MJ and RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. *Neurology* 2011;77(13):1295-304.
32. Herzog AG et al for Progesterone Trial Study Group. Variation of seizure frequency with ovulatory status of menstrual cycles. *Epilepsia* 2011;52(10):1843-8.
33. Cock HR for the ESETT Group. Established status epilepticus treatment trial (ESETT). *Epilepsia*. 2012;52 Suppl 8:50-2.
34. Langer JE, Lopes B, **Fountain NB**, Pranzatelli MR, Thiele EA, Rust RS, Goodkin HP. An unusual presentation of anti-Hu associated paraneoplastic limbic encephalitis. *Dev Med Child Neuro* 2012;Feb.
35. Engel J Jr, et al. Early randomized surgery for epilepsy trial (ERSET). *JAMA* 2012;307(9):922-930.
36. Wicks P, **Fountain NB**. Patient Assessment of Physician’s Performance of Epilepsy Quality Care Measures. *Neurology Clinical Practice* 2012;2:335-342.
37. **Fountain NB**, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd GD. Safety and tolerability of adjunctive lacosamide IV loading dose in lacosamide-naïve patients with partial-onset seizures. *Epilepsia* 2013;54(1):58-65.
38. Halford JJ, Schalkoff RJ, Zhou J, Benbadis SR, Tatum WO, Turner RP, Sinha SR, **Fountain NB**, Arain A, Pritchard PB, Kutluay E, Martz G, Edwards JC, Waters C, Dean BC. Standardized Database Development for EEG Epileptiform Transient Detection: EEGnet Scoring System and Machine Learning Analysis. *Journal Neuroscience Methods* 2013;212:308–316.
39. Hirsch LJ, Laroche SM, Gaspard N, Gerard E, Svoronos A, Herman ST, Mani R, Arif H, Jette N, Minazad Y, Kerrigan JF, Vespa P, Hantus S, Claassen J, Young GB, So E, Kaplan PW, Nuwer MR,

**Fountain NB**, Drislane FW. American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2012 version. *J Clin Neurophysiol* 2013;30:1-27

40. Winawer MR, Connors R; EPGP Investigators. Evidence for a shared genetic susceptibility to migraine and epilepsy. *Epilepsia* 2013 Feb;54:288-95.
41. Epi4K Consortium & Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopathies. *Nature* 2013;501:217-221.
42. EPGP Collaborative. The epilepsy phenome/genome project. *Clin Trials* 2013 Aug;10(4):568-86.
43. Shain C, Ramgopal S, Fallil Z, Parulkar I, Alongi R, Knowlton R, Poduri A; EPGP Investigators. Polymicrogyria-associated epilepsy: a multicenter phenotypic study from the Epilepsy Phenome/Genome Project. *Epilepsia* 2013 Aug;54(8):1368-75.
44. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, **Fountain N**, Jones E, Lowenstein D, Shinnar S, Silbergleit R, Treiman D, Trinka E, Kapur J. The established status epilepticus trial 2013. *Epilepsia* 2013;54 Suppl 6:89-92.
45. Friedman D, Fahlstrom R; EPGP Investigators. Racial and ethnic differences in epilepsy classification among probands in the Epilepsy Phenome/Genome Project (EPGP). *Epilepsy Res.* 2013;107(3):306-10.
46. Widdess-Walsh P, Dlugos D, Fahlstrom R, Joshi S, Shellhaas R, Boro A, Sullivan J, Geller E; EPGP Investigators. Lennox-Gastaut syndrome of unknown cause: phenotypic characteristics of patients in the Epilepsy Phenome/Genome Project. *Epilepsia* 2013;54(11):1898-904.
47. Greyson B, **Fountain NB**, Derr LL, Broshek DK. Out-of-Body Experiences Associated with Seizures. *Frontiers in Human Neuroscience* 2014;8:65.
48. Greyson B, **Fountain NB**, Derr LL, Broshek DK. Mystical Experiences Associated With Seizures. *Religion, Brain & Behavior* 2015;5(3):182-196.
49. Heck CN, et al. Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial. *Epilepsia* 2014;55(3):432-41.
50. Langer J, **Fountain NB**. An Observational Study of Current Treatment for Generalized Convulsive Status Epilepticus. *Epilepsy and Behavior* 2014;37:95-99.
51. Rosenfeld W, **Fountain NB**, Kaubrys G, Ben-Menachem E, McShea C, Isojarvi J, Doty P; the SP615 Study Investigators. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. *Epilepsy & Behavior* 2014;41:164-170.

52. Epilepsy Phenome/Genome Project; Epi4K Consortium; EuroEPINOMICS-RES Consortium. De Novo Mutations in Synaptic Transmission Genes Including DNMT1 Cause Epileptic Encephalopathies. *Am J Hum Genet* 2014 Oct 2;95(4):360-70.
53. Salinova et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. *Neurology* 2015;84(10):1017-25.
54. Bergey GC, Morrell M, Mizrahi EM, Goldman AM, King-Stephens D. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. *Neurology* 2015;84(8):810-7.
55. **Fountain NB**, Van Ness PC, Bennett A, Absher J, Patel AD, Sheth KN, Gloss DS, Morita DA, Stecker S. Quality improvement in neurology: Epilepsy Update Quality Measurement Set. *Neurology* 2015;84(14):1483-7.
56. Mefford, EPGP Study Group. CNV analysis from exome data in 349 patients with epileptic encephalopathy. *Ann Neurology* 2015;78(2):323-8.
57. Quigg MS, Sun F, **Fountain NB**, Jobst BC, Wong VSS, Mirro E, Brown S, Spencer DC. Interrater reliability in interpretation of electrocorticographic seizure detections of the responsive neurostimulator. *Epilepsia* 2015;56(6):968-71.
58. King-Stephens D, et al. Lateralization of Mesial Temporal Lobe Epilepsy with Long-term Ambulatory Electrocorticography. *Epilepsia* 2015;56(6):959-67.
59. Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, **Fountain NB**. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. *Epilepsy Behav* 2015;25;52(Pt A):119-127.
60. Spencer DC, Sun FT, Brown SN, Jobst B, **Fountain NB**, Wong VS, Mirro EA, Quigg M. Circadian and ultradian patterns of epileptiform discharges differ by seizure onset location during long-term ambulatory intracranial monitoring. *Epilepsia* 2016;57(9):1495-502.
61. Epi4K consortium. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. *Lancet Neurol* 2017;16(2):135-143.
62. Jobst et al. Brain-responsive neurostimulation in patients with medically intractable seizures arising from eloquent and other neocortical areas. *Epilepsia* 2017;58(6):1005-1014.
63. Geller et al. Brain-responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy. *Epilepsia* 2017;58(6):994-1004.
64. Epi4K Consortium, EuroEPINOMICS-RES Consortium, and Epilepsy Phenome Genome Project. Application of Rare Variant Transmission-Disequilibrium Tests to Epileptic Encephalopathy Trio Sequence Data. *European Journal of Human Genetics* 2017;25(7):894-899.

65. Fureman B, Freidman D, Baulac M, Glauser T, Moreno J, Dixon-Salazar T, Bagiella E, Connor J, Ferry J, Farrell K, **Fountain NB**, French J. Reducing placebo exposure in trials: Considerations from the Research Roundtable in Epilepsy. *Neurology* 2017;89(14):1507-1515.
66. Leiva-Salinas C, Quigg M, Elias WJ, Patrie JT, Flors L, **Fountain NB**, Rehm PK. Earlier seizure onset and longer epilepsy duration correlate with the degree of temporal hypometabolism in patients with mesial temporal sclerosis. *Epilepsy Research* 2017;138:105-109.
67. Epi4K Consortium. Phenotypic Analysis of 303 Multiplex Families with Common Epilepsies. *Brain* 2017;140:2144–2156.
68. Shih J, **Fountain NB**, Herman S, Bagic A, Lado F, Arnold S, Zupanc M, Riker E, Labiner D. Indications and Methodology for Video-EEG Studies in the Epilepsy Monitoring Unit. *Epilepsia* 2018;59:27-36.
69. Devinsky O, Friedman D, Duckrow R, **Fountain N**, Gwinn R, Leiphart J, Murro A, Van Ness P. SUDEP in Patients Treated with Brain Responsive Neurostimulation. *Epilepsia* 2018;59(3):555-561.
70. Barbaro N, Quigg M, Ward M, Chang E., et al. Radiosurgery versus open surgery for mesial temporal lobe epilepsy: the randomized, controlled ROSE Trial. *Epilepsia* 2018;59:1198-1207.
71. Quigg M, Barbaro N, et al. Visual field defects after radiosurgery versus temporal lobectomy for mesial temporal lobe epilepsy: findings of the ROSE Trial. *Seizure* 2018;63:62-67.
72. Heinzen EL, et al for Epi4K Consortium, Epilepsy Phenome/Genome Project. De novo and inherited private variants in MAP1B in periventricular nodular heterotopia, *PLOS Genetics* 2018;14(5):e1007281. <https://doi.org/10.1371/journal.pgen.1007281>
73. Kapur J, Shinnar S, Lowenstein D, Cloyd JC, Elm J, Bleck T, Conwit R, Coles L, Chamberlain J, Silbergleit R, **Fountain N**. Lessons from the established status epilepticus treatment trial. *Epilepsy & Behavior* 2019: accepted.
74. Langfitt J, et al. Direct and Indirect Costs associated with Stereotactic Radiosurgery or Open Surgery for Medial Temporal Lobe Epilepsy: Results from the ROSE Trial. *Epilepsia* 2019: accepted.
75. Sathe AG, Tillman H, Coles LD, Elm JJ, Silbergleit R, et al. Underdosing of Benzodiazepines in Patients with Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial. *Academic Emergency Medicine* 2019: accepted.
76. Kapur J, Elm J, Silbergleit R, Chamberlain JM, Cloyd J, et al. A randomized controlled trial of three anticonvulsant medications for established status epilepticus. 2019: accepted.
77. Morrell M. et al. Nine year prospective efficacy & safety of brain-responsive

neurostimulation for focal epilepsy. *Neurology* 2019: submitted.

78. Briglia H, Wright C, **Fountain NB**, Taplinger D. Incidence of Seizure Exacerbation and Injury Related to Football Participation in People with Epilepsy. 2019:submitted.

79. Quigg M, Skarpass T, Spencer D, **Fountain NB**, Jarosiewicz B, Morrell M. Electrographic seizure detections from continuous monitoring via a brain-responsive neurostimulator as a potential proxy for patient-reported seizures. In preparation.

80. Uysal U, Liu M, Quigg M, **Fountain NB**. Cross-sectional Study of Seizure Frequency and Freedom in Treated Epilepsy. In preparation.

### **Books, Chapters, Editorials, Other:**

1. Jew, J.Y., **Fountain, N.**, Jew, E.Y. Morphological detection of neuropeptides: comparison of methods. In: Conn P.M. Methods in Neuroscience, Vol. 6: Neuropeptide Technology. pp. 130-147, 1991.
2. **Fountain, N.B.** In-Memoriam: Eric Lothman. *Journal of Clinical Neurophysiology* 1995;12(4):400.
3. **Fountain, N.B.**, Eberhard, D. Amyloid Angiopathy (Correspondence). *Neurology* 1997;48(1):291.
4. Miller, J.Q., **Fountain, N.B.**, Editors, Neurology Recall. Baltimore: Williams and Wilkins, 1997.
5. **Fountain, N.B.** Neurology, In: Bergin J. Medical Recall. Baltimore: Williams and Wilkins, 1997.
6. **Fountain, N.B.**, Bleck T.P. Mechanism of action of drugs for status epilepticus. *Epilepsy Quarterly* 1996;4(2):5-8.
7. Dreifuss FE, **Fountain NB**. Classification of epileptic seizures and the epilepsies with drugs of choice. In: Eadie, M.J. and Vajda, F. *Handbook of Experimental Pharmacology, Vol 133: Antiepileptic Drug Pharmacology and Therapeutics*. Germany: Springer-Verlag, 1999, p 1-17.
8. **Fountain, N.B.**, Dreifuss, F.E. The future of valproate. In: Löscher, W. Milestones in Drug Therapy, Valproate. Germany: Birkhäuser, 1999, pp. 265-276.
9. **Fountain, N.B.**, Dreifuss, F.E. Seizure Disorders. In: Koller, W.C. Current Practice of Medicine, vol. 2, no. 5. Philadelphia: Current Medicine Inc, 1999, pp. 723-731.
10. **Fountain, N.B.**, Levy, R., Lublin, F., Solomon, S. Common Conditions 6: Migraine, Epilepsy, MS. *Patient Care* 1999;33:150-168.
11. **Fountain, N.B.** Case studies: Convulsive seizure. In: MyPatient.com. On-line publication, [<http://www.MyPatient.com>]. 2000.

12. **Fountain, N.B.** Seizures (Epilepsy). In: Koller, W.C. Best Practice of Medicine. New York: Micromedex. 2001.
13. **Fountain, N.B.** Seizures. In, Gotto A (ed.): DISEASEDEX(M) - General Medicine, June 18, 2004. MICROMEDEX, Greenwood Village, CO, [[www.mdx.com/products/diseasedexgeneral](http://www.mdx.com/products/diseasedexgeneral)]
14. **Fountain, N.B.** Seizures and Epilepsy in Adolescents and Adults. In: Rakel and Bope. Conn's Current Therapy, 2002. Philadelphia: WB Saunders, 2002, pp884-893.
15. **Fountain, N.B.** Seizures and Epilepsy. In: Goldmann, DR. Physicians= Information and Education Resource (PIER) . American College of Physicians-American Society of Internal Medicine. On-line publication, [<http://PIER.ACPOne.org>]. 2002. Update July 22, 2003.
16. **Fountain, N.B.** Book Review, Treatment of Epilepsy: Principles and Practice, 3<sup>rd</sup> ed. Elaine Wyllie. Neurology 2002;58:1578-1579.
17. **Fountain, N.B.** Review: Origin 7.0 Graphing Software, American Journal of Electroneurodiagnostic Technology 2002;42(3):172-172.
18. Swerdlow, R., **Fountain, N.B.**, Nathan, B. Neurology, In: Bergin J. Medical Recall, 2<sup>nd</sup> Edition. Philadelphia: Lippincott Williams and Wilkins, 2003.
19. Miller, J.Q., **Fountain, N.B.**, Editors, Neurology Recall, 2<sup>nd</sup> Edition. Philadelphia: Lippincott Williams and Wilkins, 2003.
20. Shneker B., **Fountain, N.B.** Epilepsy. Disease-A-Month 2003;49(7):426-78.
21. **Fountain, N.B.** Review: S-PLUS Statistics and Graphing Software. American Journal of Electroneurodiagnostic Technology 2003;43:265-266.
22. Ranta, A., **Fountain, N.B.** Seizures and Epilepsy in Adolescents and Adults. In: Rakel and Bope. Conn's Current Therapy, 2005. Philadelphia: Elsevier Saunders, pp 1021-1031.
23. Bassin SL, **Fountain NB**, Bleck TP. Seizures in the intensive care unit. In: Hall, Schmidt and Wood. Principles of Critical Care 3rd Edition. McGraw-Hill, 2005, pp997-1006.
24. **Fountain, N.B.** Cellular damage and the neuropathology of status epilepticus. In: FW Drislane. Status Epilepticus: A Clinical Perspective. New Jersey: Humana Press, 2005, pp181-193.
25. **Fountain NB.** Epilepsy (Seizures). In: NJ Salkind. Encyclopedia of Human Development. Sage Publishing, 2005.
26. Ranta, A., **Fountain, N.B.** Seizures and Epilepsy in Adolescents and Adults. In: Rakel and Bope. Conn's Current Therapy, 2006. Philadelphia: Elsevier, 2006, pp 1095-1105.
27. **Fountain NB**, Freeman JM. EEG is an essential clinical tool: Pro and con. Epilepsia 2006;47(Suppl. 1):23-25.

28. Kubersky L, Swerdlow, R., **Fountain, N.B.**, Nathan, B. Neurology, In: Bergin J. Medical Recall, 3<sup>rd</sup> Edition. Philadelphia: Lippincott Williams and Wilkins, 2007.
29. **Fountain NB**. Transcranial Magnetic Stimulation and Sleep Deprivation as Experimental Tools: the Excitement of Sleep Deprivation. *Epilepsy Currents* 2007;7:151-152.
30. **Fountain NB**. Is it time for routine EEG monitoring after intracerebral hemorrhage? *Neurology* 2007;69:1312-1313.
31. **Fountain NB**. Evidence for Functional Impairment But Not Structural Disease in Benign Rolandic Epilepsy. *Epilepsy Currents* 2008;8:14-16.
32. **Fountain NB**. A frontal assault on the generalized nature of JME. *Epilepsy Currents* 2008;8(6):152–153.
33. **Fountain NB**. Prognosis and Outcomes in Nonconvulsive Status Epilepticus. In: F Drislane and P Kaplan, Nonconvulsive Status Epilepticus. New York, NY: Demos, 2009, pp273-280.
34. Kubersky L, Swerdlow, R., **Fountain, N.B.**, Nathan, B. Neurology, In: Bergin J, Advanced Medicine Recall. Philadelphia: Lippincott Williams and Wilkins, 2009.
35. **Fountain NB**. A pregnant pause to consider the teratogenicity of topiramate. *Epilepsy Currents* 2009;9(2):36-38.
36. **Fountain NB**. Should Levetiracetam Replace Phenytoin for Seizure Prophylaxis After Neurosurgery? *Epilepsy Currents* 2009;9(3):71-2.
37. Kubersky L, Swerdlow, R., **Fountain, N.B.**, Nathan, B. Neurology, In: Bergin J. Advanced Medical Recall, 1<sup>st</sup> Edition. Philadelphia: Lippincott Williams and Wilkins, 2009.
38. **Fountain NB**, Cole AJ. Pharmacologic treatment of epilepsy. *CNS Spectr.* 2010 Mar;15(3 Suppl 5):4-6.
39. **Fountain NB**. Choosing Among Antiepileptic Drugs. *American Academy of Neurology Continuum* 2010;Jun 16(3):121-135.
40. Southerland A, **Fountain NB**, Nathan B. Neurology, In: Bergin J. Medicine Recall, 4<sup>th</sup> Edition. Philadelphia: Lippincott Williams and Wilkins, 2010, submitted.
41. **Fountain NB**. Manual of Antiepileptic Drug Therapy. West Islip, NY: Professional Publications Inc., 2010.
42. Wong MH, **Fountain NB**. Lacosamide for the treatment of partial-onset seizures, *Therapy* 2010, in press.

43. **Fountain NB.** Complex partial status epilepticus. In: Stern J and Servin J (Eds), Atlas of Video EEG Monitoring, New York: McGraw-Hill, 2010.
44. Huff JS, **Fountain NB.** Pathophysiology and definitions of seizures and status epilepticus. *Emergency Medicine Clinics of North America* 2011;29(1):1-13.
45. Uysal U, **Fountain NB.** Seizures and Epilepsy in Adolescents and Adults. In: Rakel and Bope. Conn's Current Therapy, 2011. Philadelphia: Elsevier, submitted.
46. Shneker BF, **Fountain NB.** Anti-Epileptic Drug Selection for Partial Onset Seizures. *Current Treatment Options in Neurology* 2012;14:356–368.
47. Wong MH, **Fountain NB.** Generalized Periodic Discharges. In: LaRoche S (ed), Handbook of ICU EEG Monitoring. New York: Demos, 2012.
48. **Fountain NB.** Obliterating the Seizure Focus in AVMs is Effective: More Clinical Data Confirming Common Sense. *Epilepsy Currents* 2013;13(1):9-10.
49. Gumnit RJ, Labiner DM, **Fountain NB**, Herman ST. Data on Specialized Epilepsy Centers. In: England MJ, Liverman CT, Schultz AM, Strawbridge LM (eds), Epilepsy Across the Spectrum, Institute of Medicine Committee on the Public Health Dimensions of the Epilepsies. Washington DC: The National Academic Press, 2012.
50. **Fountain NB.** Delivering Quality Epilepsy Care. *Curr Opinion Neuro* 2013;26:174-178.
51. **Fountain NB**, Fugate, JE. Refractory Status Epilepticus: What to put down -the anesthetics or the patient? *Neurology* 2014;82:650-651.
52. Bailey RC, **Fountain NB.** Update on the potential use of lacosamide in the treatment of partial-onset seizures. *Future Neurology* 2014, Online:5Jun2014 <https://doi.org/10.2217/fnl.14.26>
53. Fureman BE, **Fountain NB**, French JA. Epilepsy matters: A research roundtable for epilepsy. *Epilepsy Behav* 2016;63:123-124.
54. **Fountain NB** , Joshi S. Neuropathology of Generalized Convulsive Status Epilepticus. In: F Drislane, P. Kaplan. *Status Epilepticus: A Clinical Perspective (2ed)*. Switzerland: Springer, 2018.
55. **Fountain NB.** Monitoring of Antiepileptic Drug Therapy. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, submitted.

## **Abstracts:**

1. Jew, J., Fountain, N. Evaluation of procedures for ultrastructural immunohistochemistry. *Anat Record* 211(3):92a, 1985.
2. Williams, T.H., Jew, J., Fountain, N. Angiotensin II-like peptide in rat brain; with which subcellular component is it associated? *Anat Record* 211(3):215A, 1985.
3. Fountain, N.B., Kim J.S., Lee, S.I. Sleep deprivation activates epileptiform discharges independent of the effects of sleep. *J Clin Neurophysiol* 1995;12:511.
4. Fountain, N.B., Bertram, E.H., Jackson, T., Goble, J., Laws, E. 3-D reconstruction of MRI allows correlation of neocortical electroencephalographic seizure onset with cortical abnormalities. *Epilepsia* 1995;36(Suppl. 4):170.
5. Fountain, N.B., Bear J., Lothman, E.W., Bertram, E.H. Intracellular entorhinal cortex responses are epileptiform in a model of chronic epilepsy. *Epilepsia* 1996;37(Suppl.5):65.
6. Fountain, N.B., Quigg M.S., Bertram, E.H., Jackson, T., Laws, E. Characteristics and anatomic location of language abnormalities induced by cortical stimulation. *Epilepsia* 1997;38(Suppl. 8):6.
7. Armstrong, R.A., Farace, E., Fountain, N.B., Quigg M.S. Seizure frequency does not predict quality of life following diagnosis of psychogenic non-epileptic seizures. *Epilepsia* 1998;39(Suppl. 6):217.
8. Fountain, N.B., Segar, F.E., Laws, E.R., Bertram, E.H. Entorhinal-hippocampal evoked responses using macro- and micro-electrodes in human epilepsy. *Epilepsia* 1998;39(Suppl. 6):202.
9. Messenheimer JA, Haynie CJ, Risner ME and the Lamictal US 41 Pediatric Study Group. Long-term tolerability of Lamictal in Pediatric Patients. *Epilepsia* 1998;39(Suppl. 6):51.
10. Pellock J, Glauser T, Bebin M, Ritter F, Shields DS, Fountain N, Jensen C. Single-dose pharmacokinetics of levetiracetam in pediatric patients with partial epilepsy. 1999 International Epilepsy Congress.
11. Kirby D, Fountain NB., Quigg MS. Utility of a standardized ictal examination. 1999 American Association of Registered EEG Technicians.
12. Gullapalli DN, Fountain NB. Occipital intermittent rhythmic delta activity is associated with epilepsy and not encephalopathy. 1999 American Clinical Neurophysiology Society.
13. Fountain NB, Danesi M, Laws ER, Quigg MS, Bertram, III EH. Sensitivity, positive predictive value, and specificity of MRI, EEG, and Wada tests for outcome from temporal lobectomy. *Epilepsia* 1999;40(Suppl 7);201.
14. Elias J, Laws ER, Bertram EH, Fountain NB. The value of repeat surgery for patients who have failed initial operations for partial complex seizures of temporal lobe origin. *Epilepsia* 1999;40(Suppl 7);220.
15. Frucht M, Quigg MS, Schwaner C, Fountain NB. Sleep and sleep deprivation as seizure precipitants vary with epilepsy syndrome classification. *Epilepsia* 1999;40(Suppl 7):222.
16. Pellock J, Glauser T, Bebin M, Ritter F, Shields DS, Fountain N, Jensen C. Single-dose pharmacokinetics of levetiracetam in pediatric patients with partial epilepsy. *Epilepsia* 1999;40(Suppl 7):124.
17. Fountain NB, French J, Privitera M. Safety and tolerability of harkoseride for refractory partial seizures. *Epilepsia* 2000;41(Suppl 7):169.
18. Schwaner C, Fountain NB. Lifetime incidence of status epilepticus in epileptics. *Epilepsia* 2000;41(Suppl 7):251.
19. Shneker B, Fountain NB. Etiology-specific morbidity and mortality of nonconvulsive status epilepticus. *Epilepsia* 2000;41(Suppl 7):251.

20. Frucht M, Fountain NB, Schwaner C. Antiepileptic drug response of temporal lobe versus extratemporal partial epilepsy. *Epilepsia* 2000;41(Suppl 7):255.
21. Shneker B, Fountain NB. Association between EEG characteristics and mortality in nonconvulsive status epilepticus. 2000 American Clinical Neurophysiology Meeting.
22. Fountain NB, Pellock J, Glauser T, Bebin M, Shields D. Levetiracetam: single dose pharmacokinetics, and open-label efficacy and safety in children with partial onset seizures. 2000 European Congress of Epileptology.
23. Shneker B, Fountain NB. Epilepsy as chronic sequelae following nonconvulsive status epilepticus. *Epilepsia* 2001;42(Suppl 7):147.
24. Waldman WA., Fountain NB, Schwaner C. Differential effects of the menstrual cycle on partial seizures due to temporal lobe epilepsy. *Epilepsia* 2001;42(Suppl 7):267.
25. Fountain NB, Prasad A, Bertram EH, Quigg MS, Laws E. Positive predictive value of presurgical test combinations for good outcome from temporal lobectomy. *Epilepsia* 2001;42(Suppl 7):285.
26. May A, Fountain NB, Schwaner C. Incidence of family history of seizures in patients with classified seizure types and epilepsy syndromes. *Epilepsia* 2001;42(Suppl 7):140-141.
27. Kirby DK, Fountain NB, Quigg MS. Developing new tools for intensive monitoring support staff. American EEG Technologists Annual Meeting, 2002.
28. Epps S, Schwaner C, Waldman W, Fountain NB. Status epilepticus as the first seizure in epilepsy. *Epilepsia* 2002;43(Suppl 7):282.
29. Shneker B, Quigg MS, Fountain NB. Inconsistency of mental status examination when diagnosing nonconvulsive status epilepticus. *Epilepsia* 2002;43(Suppl 7):285.
30. Roehl H, Fountain NB, Bender SD, Mattingly J. Differences in QOLIE-10 in pseudoseizures and epilepsy. *Epilepsia* 2002;43(Suppl 7):96.
31. Sachdeo R, Beydoun A, Hull R, Fountain N, Witt P, Doty P, Rudd D. An open label, dose titration trial to evaluate tolerability and efficacy of oral SPM 927 as adjunctive therapy in patients with partial seizures. *Neurology* 2003;60(Suppl 1):433.
32. Sachdeo R, Montouris G, Beydoun A, Hull R, Fountain N, Doty P, Rudd D, Summerville K. An open label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures. 2003 European Federation of Neurological Societies.
33. Kirby D, Quigg MS, Shneker B, Fountain NB. The value of standardized testing in nonconvulsive status diagnosis. *American Journal of Electroneurodiagnostic Technology* 2003;43:241.
34. Fountain NB, Horstmann R, Cawello W, Doty P, Rudd GD. Absence of effect of adjunctive SPM 927 on concomitant AED plasma concentrations in subjects with partial seizures. AES 2003.
35. Taft WC, Fountain NB. Long Term Outcome in Lennox-Gastaut Syndrome. AES 2003.
36. Martinez JF, Fountain NB. Frequency of myoclonic seizure exacerbation by lamotrigine in JME. AES 2003.
37. Elias JW, Quigg M, Laws ER, Fountain NB. A comparison of the associated morbidity with intracranial monitoring and resective surgery for extratemporal and temporal lobe epilepsy. AES 2003.
38. Taft WC, Fountain NB. Seizure freedom in Lennox-Gastaut Syndrome. *Epilepsia* 2004;45(Suppl 7):96-97.
39. Ranta A, Fountain NB. Characterization of tumor-related epilepsy. *Epilepsia* 2004;45(Suppl 7):282.

40. Fountain NB, Thompson SR. Long term safety and tolerability of bromides for intractable seizures. *Epilepsia* 2004;45(Suppl 7):132-133.
41. Thompson SR, Palmer B, Fountain NB. Clinical drug study participation improves seizure frequency. *Epilepsia* 2004;45(Suppl 7):144.
42. Martinez JF, Fountain NB. Clinical characteristics of refractory JME. *Epilepsia* 2004;45(Suppl 7):103.
43. Sahoo SK, Goodkin H, Fountain NB. Latency to onset of pseudoseizures. *Epilepsia* 2004;45(Suppl 7):143.
44. Biton V, Rosenfeld WE, Fountain NB, Vaiciene N, Whitesides JG, Sommerville KW. Safety, Tolerability and Pharmacokinetics of Intravenous Lacosamide as Replacement for Oral Lacosamide in Subjects with Partial Seizures. American Academy of Neurology 2005 meeting.
45. Wright CJ, Fountain NB. Reported football related injuries in patients with epilepsy. *Epilepsia* 2005;46(Suppl 8):364.
46. Fountain NB, Liu M. Refractoriness of seizure types and epilepsy syndromes. *Epilepsia* 2005;46(Suppl 8):341.
47. Liu M, Fountain NB. Demographics and AED Use of Seizure Types and Epilepsy Syndromes. *Epilepsia* 2005;46(Suppl 8):348.
48. Liu M, Fountain NB. Rate of seizure freedom in epilepsy. 2006 AES.
49. Fountain NB, Liu M. Ontogeny of seizure freedom. 2006 AES.
50. Williams K, Martinez JF, Fountain NB. Physician perceptions of epilepsy in El Salvador. 2006 AES.
51. Lu Z, Fountain NB, Conry JA, Rodríguez-Leyvac I, Gutierrez-Moctezuma J, Salas E, Coupez R, Stockis A. Levetiracetam Pharmacokinetics During Dose Escalation in 4- to 12-Year-Old Children With Partial-Onset Seizures on Concomitant Carbamazepine or Valproate, 2006 AES.
52. Rosenfeld W, Fountain NB, Kaubrys G, Heinzen L, McShea C, and the SP615 Study Team. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures. 2007 AES.
53. Elias WJ, Liu M, Fountain NB. Refractoriness of tumor-related epilepsy. AES 2007.
54. Elias J, Sansur C, Frysinger R, Fountain. Risk/Benefit Analysis in the Surgical Treatment of Temporal Lobe Epilepsy. American Association of Neurosurgeons Annual Meeting, 2008.
55. Fountain NB, Liu M. Natural history of seizure patterns in new-onset epilepsy. AES 2008.
56. Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report. International Epilepsy Congress 2009.
57. Biton V, Fountain NB, Rosenow F, Gil-Nage A, Sullivan T, Hebert D, Doty P. Safety and Tolerability of Lacosamide: A Summary of Adverse Events in Epilepsy Clinical Trials. AAN 2009.
58. Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report. Innsbruck Status Epilepticus Conference 2009.
59. Biton V, Gil-Nage A, Fountain NB, Rosenow F, Hebert D, Doty P. The Safety and Tolerability of Lacosamide as Adjunctive Treatment for Partial-Onset Seizures in Randomized, Double-Blind, Placebo-Controlled Phase II/III Clinical Trials at approved doses. EFNS 2009.
60. VonGaudecker J, Fountain NB. Prevalence of Epilepsy-related Death in an Epilepsy Clinic. AES 2009.

61. Langer J, Tholpady A, Liu M., Fountain NB. Duration of Epilepsy and Occurrence of Status Epilepticus. AES 2009.
62. Fountain NB, Kraus G, Sojarvi J, Dilley D, Doty P. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report. AES. *Epilepsia* 2009;50(Suppl 11):257-258.
63. Fountain NB, Kraus G, Isojarvi J, Dilley D, Doty P, Rudd GD. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report. AAN 2010.
64. Fountain NB, Kraus G, Isojarvi J, Dilley D, Doty P, Rudd GD. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in patients with partial-onset seizures. ECE 2010.
65. Wong M, Fountain NB. The Frequency of PLEDS as an Ictal Pattern in Nonconvulsive Status Epilepticus, AES 2010.
66. Langer J, Fountain NB. Reliability of status epilepticus coding in the emergency department, AES 2010.
67. Uysal U, Fountain NB. Prospective Analysis of Seizure Frequency in Established Epilepsy. AES 2010.
68. Wicks P, Fountain NB. Patient-reported clinician adherence to epilepsy performance measures of quality care. AAN 2011.
69. Van Ness PC, Fountain NB, Duckrow RB, Gwinn RP, Leiphart JW. Electrographic Events Preceding Sudden Unexplained Death in Epilepsy (SUDEP). AES 2011.
70. Langer JE, Fountain NB. Response of generalized status epilepticus to first, second, and third line therapy. AES 2011.
71. Uysal U, Liu M, Fountain NB. Prospective Analysis of Seizure Freedom in Established Epilepsy. AES 2011.
72. J. Wolfe, S. R. Benbadis, W. O. Tatum, R. P. Turner, A. Arain, N. B. Fountain, S. R. Sinha, P. B. Pritchard, G. U. Martz, E. Kutluay, J. C. Edwards, B. Comparison Of Binary And Ordinal Scoring For Epileptiform Transient Detection. AES 2012.
73. Afeefy H, Uysal U, Fountain NB. Low Prevalence of Mesial Temporal Lobe Epilepsy May Account for Decline in Temporal Lobectomy. AES 2013
74. Langer JE, Fountain NB. Common use but low efficacy of phenytoin for status epilepticus. AES 2013
75. Fountain NB. Potential of Focused Ultrasound in Epilepsy Surgery, : International Symposium on Focused Ultrasound 2014
76. Quigg MS, et al. Interrater reliability in interpretation of electrocorticographic seizure detections of the responsive neurostimulator, AES 2014.
77. Tseng P, Liu M, Fountain NB. Evidence Mesial TLE Is Not Always Medically Refractory, AES 2014
78. Spencer D, Sun F, Brown S, Jobst B, Fountain N, Wong V, Mirro E, Quigg M. Circadian Patterns of Epileptiform Activity from Long-term Intracranial Recordings in Ambulatory Subjects. AES 2015
79. Uysal U, Quigg MS, Liu M, Fountain NB. Seizure Frequency Distribution of Common Epilepsy Trial Cohorts: Too Many Have Too Few, AES 2015
80. Van Ness P, et al. Long-Term Outcome Of Adults With Medically Intractable Mesial

Temporal Lobe Seizures Treated With Responsive Neurostimulation, AES 201.

81. Jobst B, et al. Long-term outcome of adults with medically intractable frontal lobe seizures treated with responsive, AES 2015.
82. Bajo SD, De Marco AP, Mahoney III JJ, Reno AJ, Aduen P, Broshek D, Fountain N. Prospective Memory in Epilepsy: Preliminary Findings, AES 2015.
83. Tseng P, Liu M, Quigg M, Uysal U, Elias WJ, Fountain N. Durability of Outcomes in Mesial Temporal Lobe Epilepsy, AES 2015
84. Spencer D, Sun F, Brown S, Jobst B, Fountain N, Wong V, Mirro E, Quigg M. Circadian Patterns of Epileptiform Discharges Differ by Seizure Onset Location During Chronic, Long-Term Intracranial Monitoring, AAN 2016.
85. Devinsky O, Kapur R, Duckrow RB, Fountain NB, Gwinn RP, et al. SUDEP Rate in Patients with Medically Intractable Partial Onset Seizures Treated with Brain RNS. AES 2016
86. Bauer D, Fountain NB. Seizure Characteristics in Adult Tuberous Sclerosis. AES 2016
87. Leiva-Salina C, Quigg M, Fountain NB. Voxel based analysis of metabolic abnormalities in mesial temporal lobe epilepsy. Radiological Society of North America, 2017
88. Fountain NB, Skarpaas TL, Quigg M, Spencer DC, Jobst BC, Sun FT, Desai SA, Morrell MJ. Correlations between electrographic and clinical seizures in patients treated with a responsive cortical neurostimulator. AES 2017
89. Bauer D, Kanth K, Michel V, Fountain NB. Terminal seizure frequency trends in 22 SUDEP patients. AES 2017
90. Farrell K, Fountain N, French J, Fureman B. The 2017 Research roundtable for epilepsy. AES 2017
91. Alexander H, Fountain N. Lack of seizure exacerbation by football participation. AES 2018.
92. Sathe A, et al. ESETT: A PK simulation study to assess feasibility of a sparse blood sampling approach to estimate FOS, VPA, and PHT exposures in children. AES 2018
93. Spencer DC, Quigg MS, Fountain NB, Jarosiewicz B, Sarpaas TL, Morrell J. Electrographic events recorded by a responsive neurostimulator may provide an objective assessment of clinical seizure burden. AES 2018
94. Quigg MS, et al. Mesial Volume Changes Associated With Seizure Remission After Open- or Radiosurgery for Mesial Temporal Lobe Epilepsy: Findings of the ROSE Trial. AES 2018

### **Extramural Lectures (last 5 years)**

Grouping vs Splitting: Should we Include More Than One Syndrome/More than One Seizure Type in our Clinical Trials? Antiepileptic Drug And Device Trials XV, Miami, May 22, 2019

Debate: Open label studies for proof of concept: Pro, Research Roundtable for Epilepsy, Washington DC, March 21, 2019

Epilepsy Quality Measures in the EMU, American Epilepsy Society Meeting, New Orleans, December 1, 2018

Epilepsy Care at the Crossroads – Overcoming the “Pharmacologic Ceiling”, University of Pittsburg Grand Rounds, November 7, 2018

New Technologies for Intractable Epilepsy: Focused Ultrasound and Deep Brain Stimulation, Northwestern University, June 4, 2018

Sudden Unexplained Death in Epilepsy (SUDEP), Virginia Neurological Society, Hot Springs VA, January 26, 2018

Selecting Epilepsy Treatments: Practice of Neurology, Virginia Neurological Society, Hot Springs VA, January 26, 2018

Focused Ultrasound Treatment for Epilepsy, Hot Topics American Epilepsy Society, Washington DC, December 2, 2017

Reducing placebo exposure in epilepsy trials, AED Trials XVII, Miami, May 18, 2017

New Treatments for Intractable Epilepsy, George Washington University Grand Rounds on epilepsy.com, Feb. 14, 2017

Focused Ultrasound for Epilepsy, International Hypothalamic Hamartoma Symposium, London, Sept. 16, 2016.

Hans Berger Symposium, Richmond, May 23-24, 2016  
Selecting Seizure Drugs: EEG and Other Factors,  
Epilepsy Quality Measures in Clinical Practice

Prudent use of new and old AEDs, Johns-Wooten Symposium, Charlottesville, May 14, 2016

Exercise and Epilepsy, Epilepsy Pipeline Conference, San Francisco, Feb. 27, 2016

Adhering to Epilepsy Quality Measurement Set Update, NeuroSeries Live, Richmond, VA, September 30, 2015 <https://event.webcasts.com/viewer/directLink.jsp?ei=1076582>

Innovations in Treatment of Status Epilepticus, AAN, Washington DC, April 25, 2015

Cannabinoids in the Treatment of Epilepsy, Virginia Neurological Society, January 30, 2015

Potential of Focused Ultrasound for Epilepsy, International Epilepsy Colloquium, Marburg, Germany, May 29, 2014